Thus, SUVmax could be used as a noninvasive tool to assess the tumor microenvironment including the frequency of PD‐L1 protein expression to predict benefit from antiPD‐1/PD‐L1 inhibitors. This evidence concerns the gene CD274 and neoplasm.